Our Story

MSTANDARD PHARMACEUTICAL DMCC, established in 2021, has swiftly emerged as a key player in the international pharmaceutical trade. Specializing in the trading of pharmaceutical products and medicines, the company has forged significant partnerships with countries including China, Uzbekistan, Tajikistan, Georgia, and South Korea. Among these, China, Uzbekistan, and the UAE are considered strategic partners, reflecting the company's focus on strong and sustainable international collaborations.

Within a short period, MSTANDARD PHARMACEUTICAL DMCC has launched projects worth over 10 million USD. The company's scope of operations extends beyond mere trade; it also undertakes turnkey projects for establishing production lines of medicines. These projects adhere to Good Manufacturing Practice (GMP) and ISO standards, ensuring the highest quality in pharmaceutical production. Each production step is outfitted with top-tier equipment, underscoring the company's commitment to quality and compliance.

By 2022, MSTANDARD PHARMACEUTICAL DMCC had successfully completed 77% of its contracts, highlighting its efficiency and reliability. The company is dedicated to supporting its clients in the international pharmaceutical trade, offering cooperation and guidance to facilitate their market activities.

Looking ahead, MSTANDARD PHARMACEUTICAL DMCC aims to expand its footprint in the global pharmaceutical industry, continuously strengthening its relationships with clients and strategic partners worldwide.